DAILY REVIEW · DATED EVIDENCE
What is changing the outlook?
Think of the original index as the long journey, and this daily adjustment as changing conditions along the way.
Today’s progress outlook — explore
DAILY CONDITIONS · EDITORIAL MODEL
Calculated 2026-11-06 UTCToday’s progress outlook
36.6 / 100Daily-adjusted Civilization Index
+2.81Points against the fixed 33.8 baseline
-0.52Points since previous recorded day
Geopolitics · resources · research · oil prices. Daily review can leave the number unchanged. This experimental model is not a scientific measurement or forecast.
What moved the score? See sources & calculation ↗Reviewed 6 November 2026: EIA's Daily Prices page dated 6 November reports Brent spot $97.96 and WTI spot $94.05 for the 5 November close, replacing $91.84 and $91.73 for the 4 November close. Only Brent is scored; its $6.12 increase lowers the fixed importer-affordability component. The observation is one calendar day old and below the greater-than-seven-day stale threshold. EIA's spot series was used, not futures; the separately labelled futures table showed no available quote. OPEC's Annual Statistical Bulletin 2026 tables reverified worldwide proven crude reserves of 1,572.46 billion barrels at end-2025 and crude production of 74.85 million barrels/day in 2025. They remain annual statistics, not daily inventory or depletion countdowns, and do not move the score. IEA reverified its 25% projected 2035 copper deficit; it is a scenario, not a present shortage or geological exhaustion. IRENA's direct release again returned 403, so 5,149 GW of renewable capacity at end-2025 and its successful 3 November review date are retained; capacity is not generation. IMO reports 129 confirmed incidents and 25 fatalities as of 6 November, with the latest record describing a damaged vessel and one fatality on 4 November. OCHA's 5 November items concern September appeal monitoring and a personal story, while its latest full situation report remains dated 29 October and published 31 October. The UN Security Council's November programme lists meetings rather than a verified conflict or route transition. These selected records document continuing harm but do not establish a new interstate-conflict onset/end or a seven-day route closure/reopening, and the oil-price move is not counted again as a geopolitical event. FDA granted accelerated approval on 5 November to Rybrevant Faspro for a new head-and-neck-cancer indication. The medicine was already FDA-approved in 2025; this is an indication extension, not the first approval of a new therapeutic mechanism, and the open-label 102-person trial relies on response endpoints with confirmatory studies required. EMA's latest PRAC outcome remains safety-review activity, not withdrawal of a credited achievement. Google Research added a 5 November prospective five-site study of smartwatch hypertension screening in 196 participants, but describes the work as exploratory and not a standalone diagnosis or commercial device. Nature's latest selected Parkinson's records remain screening, commentary and mouse-model research; selected Crohn's listings exposed no newer qualifying result. Selected ClinicalTrials.gov records show REGENERATE-PD without posted results and inflammatory-bowel-disease studies without a qualifying result. No event was added, duplicated, deactivated or reversed; the existing valve and Voceryq events each remain active once. Slower Humanity, nature, satellites, debt, IMF and medical records retain their completed 2 November weekly review and remain contextual outside daily-v1. Coverage is selected and incomplete; baseline, thresholds, event ledger and long-term scores are unchanged.
Oil, resources & observation dates
Brent crude spot price
Explore details
97.96 USD / barrel
2026-11-05 close · Brent benchmark; not a global average
Spot price, not futures. EIA's page dated 6 November reports the 5 November close. The observation is one calendar day old, below the greater-than-seven-day stale threshold. The higher price lowers the model's importer-affordability component; it is not a measure of overall welfare or a separate geopolitical-event credit.
Reviewed 2026-11-06 · EIA daily prices, republishing Refinitiv ↗
WTI crude spot price
Explore details
94.05 USD / barrel
2026-11-05 close · US WTI benchmark
Shown for comparison; not separately scored to avoid counting two oil prices.
Reviewed 2026-11-06 · EIA daily prices, republishing Refinitiv ↗
Proven crude oil reserves
Explore details
1,572.46 billion barrels
End of 2025 · Worldwide, OPEC crude-oil definition
Economically recoverable known crude under the source definition; not all petroleum in the ground or emergency storage. No daily depletion interpolation.
Reviewed 2026-11-06 · OPEC Annual Statistical Bulletin 2026 ↗
Crude oil production
Explore details
74.85 million barrels / day
2025 annual average · Worldwide, crude oil only
Used only for the illustrative reserves-to-production ratio, not as a score or total-liquids demand.
Reviewed 2026-11-06 · OPEC Annual Statistical Bulletin 2026 ↗
Renewable power capacity
Explore details
5,149 GW
End of 2025 · Worldwide
IRENA's 1 April 2026 release was retrieved successfully on 3 November and reconfirmed 5,149 GW at end-2025. Capacity is not actual generation; no daily interpolation or change from the frozen baseline.
Reviewed 2026-11-03 · IRENA Renewable Capacity Statistics 2026 ↗
Projected copper supply deficit
Explore details
25 %
2035 projection; 2026 report · Worldwide, IEA project-pipeline outlook
A projected supply gap under stated assumptions, not a measured shortage or geological exhaustion. The IEA executive summary reverified the 25% projected 2035 deficit on 6 November; no comparable change from the frozen baseline.
Reviewed 2026-11-06 · IEA Global Critical Minerals Outlook 2026 ↗
Reserves / annual crude production ≈ 57.6 years, using the two 2025 OPEC figures and 365 days. This is a static ratio, not a date when oil runs out. Reserves, production, technology, prices and policy change. The ratio is context only; emergency inventories are a different measure.
Slow-moving annual data stays dated. No daily depletion is invented. Source organisations do not endorse this model. Facts are paraphrased and attributed; linked source material retains its applicable rights.
Geopolitical context & research evidence
Geopolitical and supply pressure
The IEA September report estimates that more than 10 million barrels a day of Gulf output remained shut in during August. It also reports a 95-million-barrel fall in observed global oil inventories that month. These dated conditions establish context; they are not new events on the baseline day.
August 2026; report published 11 September 2026 · Source / related evidence ↗
Research review: approvals are checked for genuinely new mechanisms
The FDA update dated 30 September extends Camzyos (mavacamten) to pediatric patients weighing at least 30 kg with symptomatic obstructive hypertrophic cardiomyopathy. The drug was already approved for adults in 2022; this is not a first approval of a new mechanism for that condition. It carries a heart-failure boxed warning and restricted REMS access. The 29 September BIVIGAM/ASCENIV letters concern lot-release specifications, not new therapeutic mechanisms. No event points are added.
FDA update 30 September 2026; supplement letters 29 September; reviewed 1 October · Source / related evidence ↗
First size-adjustable pediatric pulmonary valve approved in the United States
FDA approved the surgically implanted Autus valve for pediatric patients with congenital pulmonary valve disease. It is designed for balloon expansion after surgery as a child grows and is the first FDA-approved valve with polymeric leaflets. The study enrolled 62 children; the first 60 had acceptable six-month blood-flow performance, but only two valves had been expanded and longer-term studies are still underway. This jurisdiction-specific first approval receives one daily-v1 research event credit; it is not evidence of a global cure or lifelong durability.
FDA approval 1 October 2026; reviewed 2 October · Source / related evidence ↗
First US plasmid DNA-based immunotherapy approved for recurrent respiratory papillomatosis
FDA granted accelerated approval to Voceryq for adults with recurrent respiratory papillomatosis, making it the first plasmid DNA-based immunotherapy approved in the United States. It is designed to stimulate an immune response against HPV types 6 and 11 and is indicated to reduce surgical papilloma excisions. The open-label trial enrolled 32 adults; seven of 26 participants with at least three baseline surgeries needed no surgery during the first year. FDA requires a controlled post-approval study because the approval uses an intermediate endpoint. This jurisdiction-specific first approval receives one daily-v1 research event credit; it is not a cure or proof of durable benefit.
FDA accelerated approval 30 October 2026; reviewed 31 October · Source / related evidence ↗
Maritime security remains a dated observation
IMO reports 122 confirmed shipping incidents and 24 confirmed seafarer fatalities as of 30 October 2026. The newly listed latest incident is damage without reported pollution to GHANA PROSPERITY in the Strait of Hormuz on 23 October, and the evacuation plan remains paused. The added dated incident does not by itself establish a qualifying new interstate-conflict onset or a seven-day route closure/reopening. No event points are added.
IMO observation 30 October 2026; latest listed incident 23 October; reviewed 31 October · Source / related evidence ↗
Parkinson’s research: laboratory finding, not a treatment milestone
A 29 September Molecular Brain study examined mouse neurons. Loss of PPM1H altered alpha-synuclein positioning; LRRK2 inhibition restored the measured positioning. This is laboratory mechanism research, not demonstrated patient benefit, gene-therapy approval or an independently replicated Civometer capability milestone. No score credit.
Published 29 September 2026; reviewed 30 September · Source / related evidence ↗
Crohn’s research: genetic regulation, not a cure
A Nature Genetics study maps gene-regulatory activity in intestinal tissue from people with Crohn’s disease and healthy controls. This observational molecular atlas is a research resource, not an approved therapy or evidence of cure. Its 25 September publication also precedes the daily baseline. No score credit.
Published 25 September 2026; reviewed 30 September · Source / related evidence ↗
Gene-delivery research: controlled activation in mice
A Nature Materials paper reports masked AAV vectors activated by selected biological signals or near-infrared light for localized gene delivery in mice. The indexed primary abstract was reviewed; direct article retrieval failed. This preclinical result is not human treatment approval, a cure or verified independent replication of a Civometer milestone. No score credit.
Published 29 September 2026; indexed abstract reviewed 1 October · Source / related evidence ↗
Cancer regimen extension: approved, but not a new mechanism
FDA approved tucatinib with trastuzumab and pertuzumab as maintenance treatment for adults with unresectable locally advanced or metastatic HER2-positive breast cancer after induction. Tucatinib and the HER2-targeted mechanism were already approved, so this regimen extension is not a first approval of a new mechanism under daily-v1. No score credit is added.
FDA approval 7 October 2026; reviewed 8 October · Source / related evidence ↗
Parkinson's gene-therapy trial: registry now says suspended
Japan's primary trial registry lists a 12-participant phase I/II Parkinson's AAV gene-therapy study as suspended, without posted results or a stated reason on the reviewed record. A suspended investigational trial is neither a cure nor a withdrawal of a previously credited achievement. No score credit or reversal is added.
Trial registry updated 7 October 2026; reviewed 8 October · Source / related evidence ↗
New US HSV treatment approval: score credit held for novelty review
FDA approved Hovilpri (pritelivir) for immunocompromised adults with HSV skin or mucosal lesions unresponsive to acyclovir, valacyclovir or famciclovir. This treats lesions; it does not cure lifelong HSV infection. Headache and drug interactions are noted by FDA. The approval is verified, but daily-v1 credit is held until the indication-specific first-mechanism requirement is established.
FDA approval 9 October 2026; reviewed 10 October · Source / related evidence ↗
Why a new US drug is not automatically a new global mechanism
Maruho reports that Japan approved amenamevir for recurrent herpes simplex on 24 February 2023 and describes its helicase-primase inhibition. Pritelivir also inhibits this complex. The products and approved populations differ; this earlier class precedent prevents assuming global mechanism novelty from the new US approval alone. Further indication-level verification is needed before any score credit.
Japanese approval 24 February 2023; manufacturer primary record reviewed 10 October 2026 · Source / related evidence ↗
Ocrevus safety update: monitoring advice, not a market withdrawal
EMA posted a healthcare-professional notice about drug-induced liver injury with ocrelizumab and liver-function monitoring. The regulatory outcome is a variation, not withdrawal of the treatment. No daily-v1 reversal is added. The notice page was accessible; its detailed PDF could not be retrieved in this review.
Dissemination 8 October 2026; publication 9 October; reviewed 10 October · Source / related evidence ↗
EMA recommendations are not final approvals or new global achievements
The October CHMP meeting recommended six medicines for approval. These opinions are not final European Commission authorisations. Rasonque already appears in FDA's list with an August 2026 approval, before the daily baseline; a later regional recommendation is not a second achievement. No daily-v1 credit is added.
CHMP meeting 12–15 October 2026; published and reviewed 16 October · Source / related evidence ↗
Roadster flight claims: manufacturer evidence, not a transport milestone
Tesla's indexed official Roadster page describes an invitation-only, single-seat Rocket version with surrounding cold-gas thrusters and says it is not approved for public-road use. These are manufacturer claims. The directly retrieved page exposed only footnotes, and the complete demonstration and performance evidence were not independently verified in this review. Routine safe flight, certification and independent replication are not established here. No daily-v1 score credit.
Manufacturer page indexed and reviewed 17 October 2026; no verified delivery date · Source / related evidence ↗
Robot touch research: an experimental component
A Nature Machine Intelligence paper reports a large sensor skin and processing architecture for robotic touch. The publisher's index and indexed abstract were reviewed; direct article retrieval failed. This is component-level research, not verified deployment of general-purpose humanoids at scale or independently replicated completion of an existing Civometer milestone. No score credit.
Paper published 16 October 2026; publisher index and abstract reviewed 17 October · Source / related evidence ↗
AI in laboratory experiments: research prototypes, not AGI
Google Research describes prototypes combining AI agents, laboratory robotics and repeated design-test cycles for molecular discovery. Its report also identifies unresolved problems in physical reasoning and experimental feedback. This is a developer's research report; independent replication, an approved treatment and completion of a pre-existing Civometer capability milestone were not verified. It does not establish AGI. No score credit.
Developer report published 16 October 2026; reviewed 17 October · Source / related evidence ↗
Eye-redness medicine: first nonprescription formulation is not automatically a new mechanism
FDA approved Brytly (apraclonidine 0.125%) for eye redness from minor irritation in people aged 12 and older on 16 October. FDA calls it the first nonprescription apraclonidine eye drop and notes that higher concentrations already have prescription uses. The approval page was retrieved successfully today. This establishes a new nonprescription option, but does not by itself establish daily-v1's first-mechanism requirement. No score credit.
United States approval 16 October 2026; reviewed 17 October · Source / related evidence ↗
Immune-cell reprogramming: mouse research, not an approved cure
MIT reports lipid nanoparticles delivering mRNA to program natural killer cells inside mice, with experimental results in cancer and autoimmune-hepatitis models. This is preclinical research, not demonstrated treatment effectiveness in humans or regulatory approval. Independent replication of a pre-existing Civometer milestone was not verified. No daily-v1 score credit.
United States research; mouse models; report published 13 October 2026; reviewed 18 October · Source / related evidence ↗
Coral extinction risk: assessment dates matter
IUCN reports 340 of 774 sufficiently assessed reef-building coral species threatened, about 44%. The reassessment considered 892 species, including 118 with insufficient data. It uses data through 2020 and does not incorporate the 2023–2025 bleaching event. This is not a count of extinctions in 2026 or a daily rate. Context only; no daily-v1 score change.
Global reef-building corals; data through 2020; release 15 October 2026; reviewed 19 October · Source / related evidence ↗
Pediatric indication extension: not a new therapeutic mechanism
FDA's EVARREST fibrin sealant patch supplement extends an already approved indication to pediatric patients across all age groups. The 16 October letter supersedes an 8 October letter and was posted on 20 October. This is an age-group extension, not a first therapeutic mechanism or a newly replicated capability milestone. No daily-v1 event credit.
United States; supplement letter 16 October 2026; posted and reviewed 20 October · Source / related evidence ↗
Hepatitis B approval: important, but not a second mechanism event
FDA lists Hibsago (bepirovirsen) as approved in the United States for certain adults with chronic hepatitis B without cirrhosis, together with existing antiviral therapy. The developer describes it as an antisense oligonucleotide. However, Japan approved the same medicine and mechanism in August 2026, before the daily-v1 baseline. A later regional approval is excluded from duplicate event credit. Manufacturer-reported trial outcomes remain specific to the selected population and do not mean every patient is cured.
Japan first global approval 24 August 2026; United States approval 20 October; reviewed 21 October · Source / related evidence ↗
Gene-therapy label supplement: storage change, not a new treatment approval
FDA's 21 October Vyjuvek supplement extends refrigerated carton storage from one month to three months and permits frozen storage of administration syringes for up to four weeks. It changes storage and handling for an already approved gene therapy; it does not approve a new mechanism, indication or patient outcome. No daily-v1 event credit.
United States supplement approval 21 October 2026; reviewed 22 October · Source / related evidence ↗
AI-assisted ultrasound: prospective diagnostic study, not an approved treatment
Google Research reports a prospective study in Chicago and Nairobi in which novice-operated blind-sweep ultrasound plus an AI research model estimated gestational age with non-inferior error compared with expert sonographer biometry. The model was tested in 385 participants across the two target cohorts, but the report describes research rather than a regulatory approval, treatment or independently replicated Civometer capability milestone. No daily-v1 event credit.
Study report published 21 October 2026; reviewed 22 October · Source / related evidence ↗
Friedreich's ataxia gene-delivery research: cell and mouse study
A Gene Therapy paper reports that triplex-purified minicircle DNA increased frataxin expression in Friedreich's ataxia patient-derived fibroblasts and in mouse liver and heart after hydrodynamic delivery. The animal endpoint was 72-hour early protein expression rather than functional rescue, and the authors identify delivery, durability, scaling and safety work still needed. This is preclinical platform research, not demonstrated human benefit, regulatory approval or independent replication of a Civometer capability milestone. No daily-v1 event credit.
Published 31 October 2026; reviewed 1 November · Source / related evidence ↗
Scored event ledger
- FDA approves first size-adjustable pediatric pulmonary heart valve
2026-10-01 · United States; pediatric patients with congenital pulmonary valve disease · first_approval
FDA premarket approval of the Autus Size-Adjustable Valve, the first heart valve designed for post-surgical expansion as a child grows and the first FDA-approved valve with polymeric leaflets. The supporting study enrolled 62 pediatric patients; the first 60 had acceptable six-month hemodynamic performance, while only two valves had been expanded and longer-term studies remain underway.
Primary evidence ↗ - FDA approves first US plasmid DNA-based immunotherapy for recurrent respiratory papillomatosis
2026-10-30 · United States; adults with recurrent respiratory papillomatosis · first_approval
FDA granted accelerated approval to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd), the first plasmid DNA-based immunotherapy approved in the United States, to reduce surgical papilloma excisions in adults with recurrent respiratory papillomatosis. The open-label multicenter study enrolled 32 adults; seven of 26 participants with at least three baseline surgeries required no surgery during the first year. Approval rests on an intermediate endpoint reasonably likely to predict benefit, requires a post-approval controlled study, and is not evidence of cure or global approval.
Primary evidence ↗
Daily history & changes
| Review date (UTC) | Daily-adjusted score | Change | Reason / coverage |
|---|---|---|---|
| 2026-11-06 | 36.61 | -0.520 | Reviewed 6 November 2026: EIA's Daily Prices page dated 6 November reports Brent spot $97.96 and WTI spot $94.05 for the 5 November close, replacing $91.84 and $91.73 for the 4 November close. Only Brent is scored; its $6.12 increase lowers the fixed importer-affordability component. The observation is one calendar day old and below the greater-than-seven-day stale threshold. EIA's spot series was used, not futures; the separately labelled futures table showed no available quote. OPEC's Annual Statistical Bulletin 2026 tables reverified worldwide proven crude reserves of 1,572.46 billion barrels at end-2025 and crude production of 74.85 million barrels/day in 2025. They remain annual statistics, not daily inventory or depletion countdowns, and do not move the score. IEA reverified its 25% projected 2035 copper deficit; it is a scenario, not a present shortage or geological exhaustion. IRENA's direct release again returned 403, so 5,149 GW of renewable capacity at end-2025 and its successful 3 November review date are retained; capacity is not generation. IMO reports 129 confirmed incidents and 25 fatalities as of 6 November, with the latest record describing a damaged vessel and one fatality on 4 November. OCHA's 5 November items concern September appeal monitoring and a personal story, while its latest full situation report remains dated 29 October and published 31 October. The UN Security Council's November programme lists meetings rather than a verified conflict or route transition. These selected records document continuing harm but do not establish a new interstate-conflict onset/end or a seven-day route closure/reopening, and the oil-price move is not counted again as a geopolitical event. FDA granted accelerated approval on 5 November to Rybrevant Faspro for a new head-and-neck-cancer indication. The medicine was already FDA-approved in 2025; this is an indication extension, not the first approval of a new therapeutic mechanism, and the open-label 102-person trial relies on response endpoints with confirmatory studies required. EMA's latest PRAC outcome remains safety-review activity, not withdrawal of a credited achievement. Google Research added a 5 November prospective five-site study of smartwatch hypertension screening in 196 participants, but describes the work as exploratory and not a standalone diagnosis or commercial device. Nature's latest selected Parkinson's records remain screening, commentary and mouse-model research; selected Crohn's listings exposed no newer qualifying result. Selected ClinicalTrials.gov records show REGENERATE-PD without posted results and inflammatory-bowel-disease studies without a qualifying result. No event was added, duplicated, deactivated or reversed; the existing valve and Voceryq events each remain active once. Slower Humanity, nature, satellites, debt, IMF and medical records retain their completed 2 November weekly review and remain contextual outside daily-v1. Coverage is selected and incomplete; baseline, thresholds, event ledger and long-term scores are unchanged. |
| 2026-11-05 | 37.13 | +1.310 | Reviewed 5 November 2026: EIA's Daily Prices page dated 5 November reports Brent spot $91.84 and WTI spot $91.73 for the 4 November close, replacing $107.03 and $99.64 for the 3 November close. Only Brent is scored; its $15.19 decline raises the fixed importer-affordability component. The observation is one calendar day old and below the greater-than-seven-day stale threshold. EIA's spot series was used, not futures; the separately labelled futures table showed no available quote. OPEC's Annual Statistical Bulletin 2026 tables reverified worldwide proven crude reserves of 1,572.46 billion barrels at end-2025 and crude production of 74.85 million barrels/day in 2025. They remain annual statistics, not daily inventory or depletion countdowns, and do not move the score. IEA reverified its 25% projected 2035 copper deficit; it is a scenario, not a present shortage or geological exhaustion. IRENA's direct release again returned 403, so 5,149 GW of renewable capacity at end-2025 and its successful 3 November review date are retained; capacity is not generation. IMO remains at 128 confirmed incidents and 24 fatalities as of 3 November; OCHA's index remains latest through the 29 October situation report published 31 October, and the UN Security Council's November programme lists meetings rather than a verified conflict or route transition. These selected records do not establish a new interstate-conflict onset/end or a seven-day route closure/reopening, and the oil-price move is not counted again as a geopolitical event. FDA's biologics index remains latest through 2 November potency guidance, not a product approval; its latest qualifying approval remains the 30 October Voceryq event already recorded once, and its novel-drug list remains latest through Hibsago on 20 October. EMA's latest PRAC outcome remains safety-review activity, not withdrawal of a credited achievement. Nature added a 4 November Parkinson's questionnaire-screening language model; it reports retrospective dataset performance, not a diagnosis approval, demonstrated treatment benefit or independent replication of a Civometer capability milestone. Nature's selected Crohn's listings exposed no newer qualifying result. Google Research has no health item newer than its 23 October tuberculosis-screening report. Selected ClinicalTrials.gov records show REGENERATE-PD without posted results and the Crohn's/ulcerative-colitis platform study without a qualifying result. No event was added, duplicated, deactivated or reversed; the existing valve and Voceryq events each remain active once. Slower Humanity, nature, satellites, debt, IMF and medical records retain their completed 2 November weekly review and remain contextual outside daily-v1. Coverage is selected and incomplete; baseline, thresholds, event ledger and long-term scores are unchanged. |
| 2026-11-04 | 35.82 | +0.030 | Reviewed 4 November 2026: EIA's Daily Prices page dated 4 November reports Brent spot $107.03 and WTI spot $99.64 for the 3 November close, replacing $107.39 and $100.06 for the 2 November close. Only Brent is scored; its $0.36 decline slightly raises the fixed importer-affordability component. The observation is one calendar day old and below the greater-than-seven-day stale threshold. EIA's spot series was used, not futures. OPEC's current Annual Statistical Bulletin 2026 tables reverified worldwide proven crude reserves of 1,572.46 billion barrels at end-2025 and crude production of 74.85 million barrels/day in 2025. They remain annual statistics, not daily inventory or depletion countdowns, and do not move the score. IEA reverified its 25% projected 2035 copper deficit; it is a scenario, not a present shortage or geological exhaustion. IRENA's direct release returned 403 today, so 5,149 GW of renewable capacity at end-2025 and its successful 3 November review date are retained; capacity is not generation. IMO reports 128 confirmed incidents and 24 fatalities as of 3 November, adding individual damaged-vessel records, while OCHA's index remains latest through the 29 October situation report published 31 October. These selected records document continuing danger but do not establish a new interstate-conflict onset/end or a seven-day route closure/reopening, and the oil-price move is not counted again as a geopolitical event. FDA's biologics index added 2 November cell-and-gene-therapy potency guidance, not a product approval; its latest qualifying approval remains the 30 October Voceryq event already recorded once, and its novel-drug list remains latest through Hibsago on 20 October. EMA's latest PRAC material concerns safety monitoring, not withdrawal of a credited achievement. Nature's latest selected Parkinson's item remains preclinical mouse research, not demonstrated human benefit, approval or independent replication; selected Crohn's listings and ClinicalTrials.gov records exposed no new qualifying result. Google Research has no health item newer than its 23 October tuberculosis-screening report. No event was added, duplicated, deactivated or reversed; the existing valve and Voceryq events each remain active once. Slower Humanity, nature, satellites, debt, IMF and medical records retain their completed 2 November weekly review and remain contextual outside daily-v1. Coverage is selected and incomplete; baseline, thresholds, event ledger and long-term scores are unchanged. |
| 2026-11-03 | 35.79 | +0.680 | Reviewed 3 November 2026: EIA's Daily Prices page dated 3 November reports Brent spot $107.39 and WTI spot $100.06 for the 2 November close, replacing $115.28 and $105.51 for the 29 October close. Only Brent is scored; the $7.89 decline raises the fixed importer-affordability component. The observation is one calendar day old and below the greater-than-seven-day stale threshold. EIA's spot series was used, not futures. OPEC's current Annual Statistical Bulletin 2026 reserve and production chart pages loaded, but their numerical chart rows were not exposed in the retrieved text, so worldwide proven crude reserves of 1,572.46 billion barrels at end-2025 and crude production of 74.85 million barrels/day in 2025 are retained with their last successful 2 November review date rather than falsely reverified today. They remain annual statistics, not daily inventory or depletion countdowns. IRENA reverified 5,149 GW of renewable capacity at end-2025, and IEA reverified its 25% projected 2035 copper deficit; capacity is not generation and the IEA value is a scenario. IMO now reports 125 confirmed incidents and 24 fatalities as of 2 November, adding three damaged ships dated 29-30 October; OCHA's index remains latest through the 29 October situation report published 31 October. These selected records document continuing danger but do not establish a new interstate-conflict onset/end or a seven-day route closure/reopening, and the oil-price move is not counted again as a geopolitical event. FDA's biologics index added 2 November cell-and-gene-therapy potency guidance, not a product approval; its latest qualifying approval remains the 30 October Voceryq event already recorded once, and its novel-drug list remains latest through Hibsago on 20 October. EMA's latest PRAC outcome remains the 30 October start of safety reviews, not withdrawal of a credited achievement. Nature's 3 November Parkinson's report concerns non-invasive oral magnetoelectric vagus-nerve neuromodulation in mouse models, not demonstrated human benefit, approval or independent replication of a Civometer milestone. Google Research has no health item newer than its 23 October tuberculosis-screening report. Selected ClinicalTrials.gov records still show REGENERATE-PD active without posted results and the Crohn's/ulcerative-colitis platform study without a qualifying result. No event was duplicated, deactivated or reversed; the existing valve and Voceryq events each remain active once. Slower Humanity, nature, satellites, debt, IMF and medical records retain their completed 2 November weekly review and remain contextual outside daily-v1. Coverage is selected and incomplete; baseline, thresholds, event ledger and long-term scores are unchanged. |
| 2026-11-02 | 35.11 | +0.000 | Reviewed 2 November 2026: EIA's page remains dated 30 October and reports Brent spot $115.28 and WTI $105.51 for the 29 October close. EIA says the page updates on weekdays, so no newer Monday quote is invented. Only Brent is scored; the unchanged observation leaves the importer-affordability contribution unchanged. The observation is four calendar days old, below the greater-than-seven-day stale threshold. OPEC's Annual Statistical Bulletin tables were retrieved successfully and reverified worldwide proven crude reserves of 1,572.46 billion barrels at end-2025 and crude production of 74.85 million barrels/day in 2025. These annual statistics are not daily inventory or depletion countdowns and do not move the score. IRENA reverified 5,149 GW of renewable capacity at end-2025, and IEA reverified its 25% projected 2035 copper deficit; capacity is not generation and the IEA value is a scenario. IMO remains at 122 confirmed incidents as of 30 October, with no newer listed incident than 23 October. OCHA's updates remain latest through the 29 October situation report published 31 October. These selected records do not establish a new interstate-conflict onset/end or a seven-day route closure/reopening; the oil-price level is not counted again as a geopolitical event. FDA's biologics index remains latest through the 30 October Voceryq approval already recorded once; its novel-drug list remains latest through Hibsago on 20 October. EMA's latest PRAC material remains the 30 October start of safety reviews of Deanxit and human normal immunoglobulin medicines, not a withdrawal of a credited achievement. Google Research has no health item newer than its 23 October tuberculosis-screening report. Selected ClinicalTrials.gov records show REGENERATE-PD active but not recruiting, with no posted results, and a Crohn's/ulcerative-colitis phase 2 platform study recruiting with estimated completion in 2031; neither is a cure, approval or qualifying daily-v1 result. A June Nature Medicine report of BBM-P002 in ten participants was added to the medical context as an uncontrolled phase 1 safety study, not efficacy proof or a score event. No event was duplicated, deactivated or reversed; the existing valve and Voceryq events each remain active once. The scheduled slower-record review successfully rechecked all 12 Humanity source links, selected FAO, IUCN, PIK, IRENA and IEA nature records, ESA satellite statistics, the IMF annual report, the OECD debt mechanism, the 12-country bond table and selected medical records. Humanity readings remain contextual and unscored; no global cultural-access or trust aggregate was invented. ESA's 23 October rounded statistics corrected functioning satellites from about 15,900 to about 15,800 and tracked objects from about 47,260 to about 47,360. The 12-country local-currency 10-year bond snapshot was updated to 2 November where available, with Brazil dated 30 October; yields remain observations, not forecasts or score inputs. Coverage remains selected and incomplete; baseline, thresholds and long-term scores are unchanged. |
| 2026-11-01 | 35.11 | +0.000 | Reviewed 1 November 2026: EIA's page remains dated 30 October and reports Brent spot $115.28 and WTI $105.51 for the 29 October close. EIA updates this page on weekdays, so no Sunday price is invented. Only Brent is scored; the unchanged observation leaves the importer-affordability contribution unchanged. The observation is three calendar days old, below the greater-than-seven-day stale threshold. OPEC's Annual Statistical Bulletin tables were retrieved successfully and reverified worldwide proven crude reserves of 1,572.46 billion barrels at end-2025 and crude production of 74.85 million barrels/day in 2025. These annual statistics are not daily inventory or depletion countdowns and do not move the score. IEA's 25% projected 2035 copper deficit was reverified unchanged. IRENA retrieval failed with 403; retain 5,149 GW at end-2025 and its last successful review date of 24 October. IMO remains at 122 validated incidents and 24 fatalities as of 30 October; the latest listed incident remains damage without reported pollution to GHANA PROSPERITY in the Strait of Hormuz on 23 October, while the evacuation plan remains paused. OCHA published its 29 October humanitarian situation report on 31 October, covering 19–25 October and documenting continuing insecurity and displacement rather than a qualifying new interstate-conflict onset/end or seven-day route closure/reopening. The oil-price level is not counted again as a geopolitical event. FDA's biologics list remains latest through the 30 October Voceryq approval already recorded once; novel-drug and safety lists exposed no newer qualifying Sunday approval or reversal. EMA's latest PRAC material remains the 30 October start of safety reviews of Deanxit and human normal immunoglobulin medicines, not a withdrawal of a credited achievement. A Nature Gene Therapy article published 31 October reports frataxin expression in patient-derived fibroblasts and a mouse model after minicircle-DNA delivery; its 72-hour animal endpoint measured early protein expression rather than functional rescue, so it is preclinical platform research, not demonstrated human benefit or independently replicated completion of a Civometer capability milestone. Google Research has no health item newer than its 23 October developer report on AI-assisted tuberculosis screening. Selected ClinicalTrials.gov Parkinson's and Crohn's records exposed ongoing studies but no newly posted qualifying result; direct page retrieval exposed no usable study details. No event was duplicated, deactivated or reversed; the existing valve and Voceryq events each remain active once. Slower Humanity, nature, satellites, debt, IMF and medical records retain their completed 26 October weekly review and remain contextual outside daily-v1. Coverage remains selected and incomplete; baseline, thresholds and long-term scores are unchanged. |
| 2026-10-31 | 35.11 | +0.620 | Reviewed 31 October 2026: EIA's page remains dated 30 October and reports Brent spot $115.28 and WTI $105.51 for the 29 October close. EIA updates this page on weekdays, so no Saturday price is invented. Only Brent is scored; the unchanged observation leaves the importer-affordability contribution unchanged. The observation is two calendar days old, below the greater-than-seven-day stale threshold. OPEC's Annual Statistical Bulletin tables were retrieved successfully and reverified worldwide proven crude reserves of 1,572.46 billion barrels at end-2025 and crude production of 74.85 million barrels/day in 2025. These annual statistics are not daily inventory or depletion countdowns and do not move the score. IEA's 25% projected 2035 copper deficit was reverified unchanged. IRENA retrieval failed with 403; retain 5,149 GW at end-2025 and its last successful review date of 24 October. IMO now reports 122 validated incidents and 24 fatalities as of 30 October; the newly listed latest incident is damage without reported pollution to GHANA PROSPERITY in the Strait of Hormuz on 23 October, while the evacuation plan remains paused. OCHA's updates index remains latest through its 27 October West Bank snapshot and its latest full situation report remains dated 22 October and published 26 October. The UN Security Council programme exposed no Saturday meeting establishing a qualifying new interstate-conflict onset/end. These selected records do not establish a seven-day route closure/reopening, and the oil-price level is not counted again as a geopolitical event. FDA granted accelerated approval on 30 October to Voceryq for adults with recurrent respiratory papillomatosis, the first plasmid DNA-based immunotherapy approved in the United States. The approval is a qualifying first-approval event and is recorded once. FDA's open-label trial enrolled 32 adults; seven of 26 participants with at least three baseline surgeries required no surgery during the first year. The approval uses an intermediate endpoint and requires a controlled post-approval study, so it is not described as a cure or proof of durable benefit. EMA's new PRAC material starts safety reviews of Deanxit and immunoglobulin hypersensitivity reports and notes precautionary batch recalls; it is not a market-wide withdrawal of a credited achievement and adds no score event. Nature's 30 October RNA-editing work and 31 October AAV-manufacturing paper are platform research, not demonstrated human benefit or independently replicated completion of a Civometer capability milestone. Google Research has no health item newer than its 23 October developer report on AI-assisted tuberculosis screening. Selected ClinicalTrials.gov records exposed ongoing Parkinson's and Crohn's studies but no new posted result satisfying daily-v1. No event was duplicated, deactivated or reversed; the existing valve event remains active once and the new Voceryq event is active once. Slower Humanity, nature, satellites, debt, IMF and medical records retain their completed 26 October weekly review and remain contextual outside daily-v1. Coverage remains selected and incomplete; baseline, thresholds and long-term scores are unchanged. |
| 2026-10-30 | 34.49 | +0.340 | Reviewed 30 October 2026: EIA's page dated 30 October reports Brent spot $115.28 and WTI $105.51 for the 29 October close, replacing $119.20 and $106.25 for 28 October. Only Brent is scored; its $3.92 decline removes the remaining importer-affordability penalty and produces a small positive price component because it is slightly below the frozen $116.01 baseline. The observation is one calendar day old, below the greater-than-seven-day stale threshold. OPEC's Annual Statistical Bulletin tables were retrieved successfully and reverified worldwide proven crude reserves of 1,572.46 billion barrels at end-2025 and crude production of 74.85 million barrels/day in 2025. These annual statistics are not daily inventory or depletion countdowns and do not move the score. IEA's 25% projected 2035 copper deficit was reverified unchanged. IRENA retrieval failed with 403; retain 5,149 GW at end-2025 and its last successful review date of 24 October. IMO remains at 121 validated incidents and 24 fatalities as of 27 October; the latest listed incident remains damage without reported pollution to LEONORA KOSAN northeast of Limah, Oman, on 23 October, while the Strait of Hormuz evacuation plan remains paused. OCHA's latest humanitarian situation report remains dated 22 October and published 26 October. The UN Security Council's 30 October programme listed Colombia, Bosnia and Herzegovina, MINURSO and UNSMIL meetings. These selected records do not establish a qualifying new interstate-conflict onset/end or seven-day route closure/reopening, and the oil-price move is not counted again as a geopolitical event. FDA's novel-drug list remains latest through Hibsago on 20 October, and its latest oncology approval remains the 26 October talazoparib combination expansion. FDA posted a Procleix Babesia/Plasmodium assay letter on 29 October, but the 6 October supplement only updates instructions, labeling and minor editorial details for existing assays. FDA device-safety and newsroom indexes exposed no newer qualifying approval or reversal. EMA's 30 October entries are periodic safety-assessment and existing-medicine updates rather than a verified first approval or withdrawal. Nature's gene-therapy index remains latest through the 28 October compact Cas12m mouse-model paper; selected Parkinson's and Crohn's listings exposed research observations but no first therapeutic approval or independently replicated Civometer capability milestone. Google Research has no health item newer than its 23 October developer report on AI-assisted tuberculosis screening. ClinicalTrials.gov loaded but exposed no study details in the retrieved text, so registry fields were not reverified. No qualifying research event or reversal was verified, and the existing valve event remains active once. Slower Humanity, nature, satellites, debt, IMF and medical records retain their completed 26 October weekly review and remain contextual outside daily-v1. Coverage remains selected and incomplete; baseline, thresholds, event ledger and long-term scores are unchanged. |
| 2026-10-29 | 34.15 | +0.340 | Reviewed 29 October 2026: EIA's page dated 29 October reports Brent spot $119.20 and WTI $106.25 for the 28 October close, replacing $123.10 and $103.37 for 27 October. Only Brent is scored; its $3.90 decline reduces the fixed importer-affordability penalty. The observation is one calendar day old, below the greater-than-seven-day stale threshold. OPEC's Annual Statistical Bulletin tables were retrieved successfully and reverified worldwide proven crude reserves of 1,572.46 billion barrels at end-2025 and crude production of 74.85 million barrels/day in 2025. These annual statistics are not daily inventory or depletion countdowns and do not move the score. IEA's 25% projected 2035 copper deficit was reverified unchanged. IRENA retrieval failed with 403; retain 5,149 GW at end-2025 and its last successful review date of 24 October. IMO remains at 121 validated incidents and 24 fatalities as of 27 October; the latest listed incident remains damage without reported pollution to LEONORA KOSAN northeast of Limah, Oman, on 23 October, while the Strait of Hormuz evacuation plan remains paused. OCHA's latest humanitarian situation report remains dated 22 October and published 26 October. The UN Security Council held a 29 October meeting on emerging technologies and security, but these selected records do not establish a qualifying new interstate-conflict onset/end or seven-day route closure/reopening. The oil-price move is not counted again as a geopolitical event. FDA's novel-drug list remains latest through Hibsago on 20 October; its latest oncology approval is the 26 October talazoparib combination expansion, and its latest biologics item remains 27 October draft guidance on individualized genome-editing submissions. EMA's current list is latest through 27 October, while the 26–29 October PRAC item is an agenda rather than a concluded regulatory outcome. None establishes a new first-mechanism approval or withdrawal. A Nature Biotechnology paper published 28 October reports engineered compact Cas12m-mediated gene activation in mouse disease models; it is preclinical research, not demonstrated human benefit, regulatory approval or independent replication of a Civometer milestone. A Nature news report about an investigational Duchenne trial was not treated as primary evidence or scored; the cited Cell paper could not be independently retrieved in this review, and the trial was never a credited event. Google Research has no health item newer than its 23 October developer report on AI-assisted tuberculosis screening. ClinicalTrials.gov loaded but exposed no study details in the retrieved text, so registry fields were not reverified. No qualifying research event or reversal was verified, and the existing valve event remains active once. Slower Humanity, nature, satellites, debt, IMF and medical records retain their completed 26 October weekly review and remain contextual outside daily-v1. Coverage remains selected and incomplete; baseline, thresholds, event ledger and long-term scores are unchanged. |
| 2026-10-28 | 33.81 | +0.430 | Reviewed 28 October 2026: EIA's page dated 28 October reports Brent spot $123.10 and WTI $103.37 for the 27 October close, replacing $128.12 and $105.25 for 26 October. Only Brent is scored; its $5.02 decline reduces the fixed importer-affordability penalty. The observation is one calendar day old, below the greater-than-seven-day stale threshold. OPEC's Annual Statistical Bulletin tables were retrieved successfully and reverified worldwide proven crude reserves of 1,572.46 billion barrels at end-2025 and crude production of 74.85 million barrels/day in 2025. These annual statistics are not daily inventory or depletion countdowns and do not move the score. IEA's 25% projected 2035 copper deficit was reverified unchanged. IRENA retrieval failed with 403; retain 5,149 GW at end-2025 and its last successful review date of 24 October. IMO remains at 121 validated incidents and 24 fatalities as of 27 October; the latest listed incident remains damage without reported pollution to LEONORA KOSAN northeast of Limah, Oman, on 23 October, while the Strait of Hormuz evacuation plan remains paused. These continuing conditions do not establish a qualifying new interstate-conflict onset/end or seven-day route closure/reopening. OCHA's latest humanitarian situation report remains dated 22 October and published 26 October; it documents continuing conditions, not a qualifying score event. The oil-price move is not counted again as a geopolitical event. FDA's novel-drug list remains latest through Hibsago on 20 October; its latest oncology approval is the 26 October talazoparib combination expansion. FDA's latest biologics item remains 27 October draft guidance on individualized genome-editing product submissions. These are not a new first-mechanism approval under daily-v1; device-safety and newsroom listings also expose no newer qualifying event. EMA's current list is latest through 27 October and contains medicine updates and paediatric investigation plans, not a verified first approval or withdrawal. Nature Neuroscience lists a 26 October Parkinson's paper reporting cellular and mouse-model findings about NUS1 deficiency and iron regulation; it is preclinical mechanism research, not demonstrated human benefit or a cure. Google Research has no health item newer than its 23 October developer report on AI-assisted tuberculosis screening. ClinicalTrials.gov loaded but exposed no study details in the retrieved text, so registry fields were not reverified. No qualifying research event or reversal was verified, and the existing valve event remains active once. Slower Humanity, nature, satellites, debt, IMF and medical records retain their completed 26 October weekly review and remain contextual outside daily-v1. Coverage remains selected and incomplete; baseline, thresholds, event ledger and long-term scores are unchanged. |
| 2026-10-27 | 33.38 | +0.010 | Reviewed 27 October 2026: EIA's page dated 27 October reports Brent spot $128.12 and WTI $105.25 for the 26 October close, replacing $128.30 and $109.72 for 23 October. Only Brent is scored; its $0.18 decline slightly reduces the fixed importer-affordability penalty. The observation is one calendar day old, below the greater-than-seven-day stale threshold. Both OPEC ASB table retrievals failed with 403 responses; retain worldwide crude reserves of 1,572.46 billion barrels at end-2025 and production of 74.85 million barrels/day in 2025 with their last successful review date of 20 October. IEA's 25% projected 2035 copper deficit was reverified unchanged. IRENA retrieval failed with 403; retain 5,149 GW at end-2025 and its last successful review date of 24 October. IMO now reports 121 validated incidents and 24 fatalities as of 27 October; its newly listed latest incident is damage without reported pollution to LEONORA KOSAN northeast of Limah, Oman, on 23 October, while the Strait of Hormuz evacuation plan remains paused. This additional incident does not establish a qualifying new interstate-conflict onset/end or seven-day route closure/reopening. OCHA's latest humanitarian situation report remains dated 22 October and published 26 October; it documents continuing conditions, not a qualifying score event. The oil-price move is not counted again as a geopolitical event. FDA's novel-drug list remains latest through Hibsago on 20 October. FDA added 27 October draft guidance on individualized genome-editing product submissions and a 26 October talazoparib combination approval for an expanded prostate-cancer setting; neither is a first approval of a new mechanism under daily-v1. Biologics otherwise remains through the 21 October Vyjuvek update, device safety has no newer communication, and press announcements remain latest through 22 October. EMA's current list is latest through 26 October and contains medicine updates, paediatric investigation plans and meeting material, not a verified first approval or withdrawal. Nature's latest gene-therapy listing remains a 26 October prenatal-therapy review, not a treatment approval or independently replicated capability milestone. Google Research has no item newer than its 23 October developer report on AI-assisted tuberculosis screening. ClinicalTrials.gov loaded but exposed no study details in the retrieved text, so registry fields were not reverified. No qualifying research event or reversal was verified, and the existing valve event remains active once. Slower Humanity, nature, satellites, debt, IMF and medical records retain their completed 26 October weekly review and remain contextual outside daily-v1. Coverage remains selected and incomplete; baseline, thresholds, event ledger and long-term scores are unchanged. |
| 2026-10-26 | 33.37 | -0.250 | Reviewed 26 October 2026: EIA's page dated 26 October reports Brent spot $128.30 and WTI $109.72 for the 23 October close, replacing $125.39 and $104.27 for 22 October. Only Brent is scored; the higher value increases the fixed importer-affordability penalty. The observation is three calendar days old, below the greater-than-seven-day stale threshold. Both OPEC ASB table retrievals failed with 403 responses; retain worldwide crude reserves of 1,572.46 billion barrels at end-2025 and production of 74.85 million barrels/day in 2025 with their last successful review date of 20 October. IEA's 25% projected 2035 copper deficit was reverified unchanged. IRENA retrieval failed with 403; retain 5,149 GW at end-2025 and its last successful review date of 24 October. IMO remains at 120 incidents and 24 fatalities as of 22 October; its latest listed incident remains SOYIA damage southeast of Al Faw, Iraq, on 20 October, and the Strait of Hormuz evacuation plan remains paused. OCHA published a 22 October humanitarian report on 26 October; it documents continuing conditions, not a qualifying new interstate-conflict onset/end or seven-day route change. The oil-price move is not counted again as a geopolitical event. FDA's novel-drug list remains latest through Hibsago on 20 October; biologics through the 21 October Vyjuvek update; device safety has no newer communication; and the latest press announcement remains the 22 October neuroscience-development programme rather than a therapy approval. EMA's latest records remain dated 23 October and include page updates, meeting material and vaccine-development guidance, not a first approval or withdrawal; EMA warned that search results may be incomplete. Nature added a 26 October prenatal-therapy review, not a treatment approval or independently replicated capability milestone. Google Research has no item newer than its 23 October developer report on AI-assisted tuberculosis screening. ClinicalTrials.gov pages loaded but exposed no study details in the retrieved text, so registry fields were not reverified. No qualifying research event or reversal was verified, and the existing valve event remains active once. The weekly review rechecked all 12 Humanity indicators without inventing global cultural-access or belief-trust aggregates; reverified selected nature and planetary-boundary sources without changing observations; updated ESA's approximate tracked-object count to 47,260 as of 23 October; refreshed all 12 sovereign ten-year yields from the linked provider; and rechecked IMF and selected medical records. These contextual updates do not enter daily-v1. Coverage remains selected and incomplete; baseline, thresholds, event ledger and long-term scores are unchanged. |
| 2026-10-25 | 33.62 | +0.000 | Reviewed 25 October 2026: EIA's page remains dated 23 October and still reports Brent spot $125.39 and WTI $104.27 for the 22 October close. This is the latest available weekday publication during the Sunday review. Only Brent is scored; the unchanged observation leaves the fixed importer-affordability contribution unchanged. The observation is three calendar days old, below the seven-day stale threshold. Both OPEC ASB table retrievals failed with 403 responses; retain worldwide crude reserves of 1,572.46 billion barrels at end-2025 and production of 74.85 million barrels/day in 2025 with their last successful review date of 20 October. IEA's 25% projected 2035 copper deficit was reverified unchanged. IRENA retrieval failed with 403; retain 5,149 GW at end-2025 and its last successful review date of 24 October. IMO remains at 120 incidents and 24 fatalities as of 22 October; its latest listed incident remains SOYIA damage southeast of Al Faw, Iraq, on 20 October, and evacuation remains paused. The UN Palestine index still leads with its 22 October West Bank olive-harvest report. These records do not establish a qualifying new interstate-conflict onset/end or seven-day route change, and the oil-price level is not counted again as a geopolitical event. FDA's novel-drug list remains latest through Hibsago on 20 October; biologics remain latest through the 21 October Vyjuvek storage supplement, device safety has no newer communication, and the latest press announcement remains the 22 October neuroscience-development program rather than a therapy approval. EMA's latest records remain dated 23 October and include page updates, meeting material and Ebola-vaccine development guidance, not a first approval or withdrawal; EMA also warned that search results could be incomplete. Nature's gene-therapy index remains latest at the 22 October News & Views feature about 20 October RNA-editing research. Google Research's latest indexed item remains its 23 October developer report on AI-assisted tuberculosis screening; it is not a therapeutic approval or independently reverified completion of a pre-existing Civometer milestone. ClinicalTrials.gov retrieval was unavailable. No independently replicated Civometer milestone or qualifying reversal was verified. No event is added, duplicated, deactivated or reversed; the existing valve event remains active once. All other scoring inputs and long-term scores are unchanged. Coverage is selected and incomplete; the deeper weekly review remains dated 19 October. |
| 2026-10-24 | 33.62 | +0.000 | Reviewed 24 October 2026: EIA's page remains dated 23 October and still reports Brent spot $125.39 and WTI $104.27 for the 22 October close. This is the latest available weekday publication during the weekend review. Only Brent is scored; the unchanged observation leaves the fixed importer-affordability contribution unchanged. The observation is two calendar days old, below the seven-day stale threshold. Both OPEC ASB table retrievals failed with 403 responses; retain worldwide crude reserves of 1,572.46 billion barrels at end-2025 and production of 74.85 million barrels/day in 2025 with their last successful review date of 20 October. IEA's 25% projected 2035 copper deficit was reverified unchanged. IRENA was retrieved successfully and reconfirmed 5,149 GW at end-2025. IMO remains at 120 incidents and 24 fatalities as of 22 October; its latest listed incident remains SOYIA damage southeast of Al Faw, Iraq, on 20 October, and evacuation remains paused. The UN Palestine index still leads with its 22 October West Bank olive-harvest report. These records do not establish a qualifying new interstate-conflict onset/end or seven-day route change, and the oil-price level is not counted again as a geopolitical event. FDA's novel-drug list remains latest through Hibsago on 20 October; biologics remain latest through the 21 October Vyjuvek storage supplement, device safety has no newer communication, and the latest press announcement is the 22 October neuroscience-development program rather than a therapy approval. EMA's latest records remain dated 23 October and include page updates, meeting material and Ebola-vaccine development guidance, not a first approval or withdrawal; EMA also warned that search results could be incomplete. Nature's gene-therapy index remains latest at the 22 October News & Views feature about 20 October RNA-editing research. Google Research added a 23 October developer report on AI-assisted tuberculosis screening, including deployment and partner-certification claims, but it is not a therapeutic approval or independently reverified completion of a pre-existing Civometer milestone. ClinicalTrials.gov retrieval was unavailable. No independently replicated Civometer milestone or qualifying reversal was verified. No event is added, duplicated, deactivated or reversed; the existing valve event remains active once. All other scoring inputs and long-term scores are unchanged. Coverage is selected and incomplete; the deeper weekly review remains dated 19 October. |
| 2026-10-23 | 33.62 | -0.690 | Reviewed 23 October 2026: EIA reports Brent spot $125.39 and WTI $104.27 for the 22 October close, replacing $117.37 and $103.95 for 21 October. Only Brent is scored; its higher level increases the fixed importer-affordability penalty. The observation is one calendar day old, below the seven-day stale threshold. Both OPEC ASB table retrievals failed with 403 responses; retain worldwide crude reserves of 1,572.46 billion barrels at end-2025 and production of 74.85 million barrels/day in 2025 with their last successful review date of 20 October. IEA's 25% projected 2035 copper deficit was reverified unchanged. IRENA retrieval failed with 403; retain 5,149 GW and its last successful review date of 15 October. IMO remains at 120 incidents and 24 fatalities as of 22 October; its latest listed incident remains SOYIA damage southeast of Al Faw, Iraq, on 20 October, and evacuation remains paused. The UN Palestine index still leads with its 22 October West Bank olive-harvest report. These records do not establish a qualifying new interstate-conflict onset/end or seven-day route change, and the oil-price movement is not counted again as a geopolitical event. FDA's novel-drug list remains latest through Hibsago on 20 October; biologics remain latest through the 21 October Vyjuvek storage supplement, and device safety has no newer communication. EMA's 23 October records include page updates, meeting material and joint Ebola-vaccine development guidance, not a first approval or withdrawal; EMA also warned that search results could be incomplete. Nature's gene-therapy index remains latest at the 22 October News & Views feature about 20 October RNA-editing research. Google Research remains latest at the 21 October prospective ultrasound study. No independently replicated Civometer milestone or qualifying reversal was verified. No event is added, duplicated, deactivated or reversed; the existing valve event remains active once. All other scoring inputs and long-term scores are unchanged. Coverage is selected and incomplete; the deeper weekly review remains dated 19 October. |
| 2026-10-22 | 34.31 | -0.180 | Reviewed 22 October 2026: EIA reports Brent spot $117.37 and WTI $103.95 for the 21 October close, replacing $115.22 and $107.89 for 20 October. Only Brent is scored; the higher Brent reading turns the fixed importer-affordability component slightly negative. The observation is one calendar day old, below the seven-day stale threshold. Both OPEC ASB table retrievals failed with 403 responses; retain worldwide crude reserves of 1,572.46 billion barrels at end-2025 and production of 74.85 million barrels/day in 2025 with their last successful review date of 20 October. IEA's 25% projected 2035 copper deficit was reverified unchanged. IRENA retrieval failed with 403; retain 5,149 GW and its last successful review date of 15 October. IMO now reports 120 incidents and 24 fatalities as of 22 October, including SOYIA damage southeast of Al Faw, Iraq, on 20 October; evacuation remains paused. The UN Palestine index added a 22 October account of escalating West Bank olive-harvest violence. These conditions do not establish a qualifying new interstate-conflict onset/end or seven-day route change. FDA's novel-drug list remains latest through Hibsago on 20 October. FDA's 21 October Vyjuvek letter changes storage and handling for an existing gene therapy, not a first mechanism approval. FDA device-safety and EMA records exposed no qualifying approval or reversal. Nature's gene-therapy index added a 22 October News & Views feature about a 20 October RNA-editing paper; direct retrieval failed, and neither an approval nor independent replication was established. Google Research's 21 October prospective AI-assisted ultrasound study reports diagnostic performance in Chicago and Nairobi, but it is research rather than an approved treatment or independently replicated Civometer milestone. No event is added, duplicated or reversed; the existing valve event remains active once. All other scoring inputs and long-term scores are unchanged. Coverage is selected and incomplete; the deeper weekly review remains dated 19 October. |
| 2026-10-21 | 34.49 | +0.310 | Reviewed 21 October 2026: EIA reports Brent spot $115.22 and WTI $107.89 for the 20 October close, replacing $118.82 and $110.01 for 19 October. Only Brent is scored; the lower price turns the fixed importer-affordability component slightly positive. The observation is one calendar day old, below the seven-day stale threshold. Both OPEC ASB table retrievals failed with 403 responses; retain worldwide crude reserves of 1,572.46 billion barrels at end-2025 and production of 74.85 million barrels/day in 2025 with their last successful review date of 20 October. IEA's 25% projected 2035 copper deficit was reverified unchanged. IRENA retrieval failed with 403; retain 5,149 GW and its last successful review date of 15 October. IMO now reports 119 incidents and 24 fatalities as of 21 October, including a second attack on AL DASMA on 20 October; evacuation remains paused. UN Palestine's latest item remains 20 October. These conditions do not establish a qualifying new interstate-conflict onset/end or seven-day route change. FDA's novel-drug list added Hibsago on 20 October. The medicine's first global approval occurred in Japan on 24 August, before the daily baseline, so the United States approval is not a second mechanism event. FDA biologics, device-safety and EMA update records were scanned; no qualifying reversal was verified. Nature's gene-therapy index still lists the three 20 October research papers reviewed yesterday; no new 21 October item or independently replicated Civometer milestone was verified. Google Research has no 21 October listing. No event is added, duplicated or reversed; the existing valve event remains active once. All other scoring inputs and long-term scores are unchanged. Coverage is selected and incomplete; the deeper weekly review remains dated 19 October. |
| 2026-10-20 | 34.18 | +0.040 | Reviewed 20 October 2026: EIA reports Brent spot $118.82 and WTI $110.01 for the 19 October close, replacing $119.33 and $108.21 for 16 October. Only Brent is scored; the lower price reduces the fixed importer-affordability penalty. The observation is one calendar day old, below the seven-day stale threshold. OPEC's annual world crude reserves of 1,572.46 billion barrels at end-2025 and production of 74.85 million barrels/day in 2025 were reverified unchanged. IEA's 25% projected 2035 copper deficit was reverified unchanged. IRENA retrieval failed twice; retain 5,149 GW and its last successful review date of 15 October. IMO retains 114 incidents and 24 fatalities as of 19 October, and evacuation remains paused. UN Palestine's 20 October report describes continuing violence and humanitarian pressures; direct DPPA and UN Security Council press-record retrievals failed. No qualifying new interstate-conflict onset/end or seven-day route change was verified. FDA novel-drug, biologics, device-safety and EMA update records were scanned. FDA's newly posted EVARREST letter extends an existing indication to pediatric age groups, not a new mechanism. Hovilpri's novelty hold remains; no qualifying reversal was verified in the selected checks. Nature's 20 October gene-therapy listings include RNA editing, tumor-targeted virus and mouse bone research, but all three linked articles failed to load; no full-paper verification or independent replication is claimed. Google Research's latest listed laboratory-agent report remains 16 October. No research event is added or repeated. The existing valve event remains active once. All other scoring inputs and long-term scores are unchanged. Coverage is selected and incomplete; the deeper weekly context review remains dated 19 October. |
| 2026-10-19 | 34.14 | +0.610 | Reviewed 19 October 2026: EIA's new 16 October close is Brent spot $119.33 (previously $126.35 for 15 October) and WTI $108.21. Only Brent is scored; its lower level reduces the fixed oil-price affordability penalty. The observation is three calendar days old, below the stale threshold. OPEC annual crude reserves of 1,572.46 billion barrels and production of 74.85 million barrels/day, both for 2025, were reverified unchanged. IEA's 25% projected 2035 copper deficit was reverified unchanged. IRENA retrieval failed twice; retain 5,149 GW at end-2025 and its successful 15 October review date. IMO now reports 114 incidents and 24 seafarer fatalities as of 19 October, including ST3 damage on 16 October; evacuation remains paused. UN Palestine was reviewed and direct DPPA retrieval failed. No qualifying new interstate-conflict onset/end or seven-day route change was verified; proposals and individual incidents are not new ledger events. FDA novel-drug, biologics and device-safety records and EMA updates were scanned. Hovilpri novelty remains unresolved; no qualifying new approval or reversal was verified. Selected Cambridge materials research and Google Research updates do not establish replicated completion of an existing milestone or AGI. The weekly review refreshed all 12 bond-yield quotes, ESA tracked objects and selected review metadata; debt estimates retain their April vintage because a complete October country table was not verified. Bemdaneprocel's four-year sponsor conference follow-up and IUCN's coral assessment were added as non-scoring context. Neither changes the ledger. Original scores remain unchanged. Coverage is selected and incomplete, with registry, journal, UNEP and WVS verification gaps recorded in the review log. |
| 2026-10-18 | 33.53 | +0.000 | Reviewed 18 October 2026: EIA still displays Brent spot $126.35 and WTI $104.71 for the 15 October close, three calendar days old and below the stale threshold. Only Brent is scored. OPEC's annual worldwide crude reserves (1,572.46 billion barrels at end-2025) and production (74.85 million barrels/day in 2025) were reverified unchanged. IEA retrieval failed twice and IRENA retrieval failed; retain the 25% projected 2035 copper gap and 5,149 GW end-2025 renewable capacity with their last successful review dates, 17 and 15 October respectively. IMO still reports 113 confirmed incidents and 24 fatalities as of 14 October and paused evacuations. The UN Palestine index was scanned; direct DPPA weekly retrieval failed. An 18 October news report describes a conditional Hormuz reopening proposal, not a verified implemented reopening. No qualifying new interstate-conflict onset/end or seven-day route change was verified. FDA novel-drug, biologics and device-safety records and the EMA updates index were checked. Hovilpri's novelty hold remains. A company notice hosted by FDA recalls specified Argatroban lots, not the credited valve or an entire therapeutic mechanism. No qualifying reversal was verified in these selected checks. MIT's 13 October immune-cell reprogramming report describes mouse research, not an approved human treatment. Nature's gene-therapy listing and selected NASA material were also reviewed; image publication, experimental research and terminology changes do not establish a new replicated capability or AGI. The existing valve event remains active once. No comparable scoring input or qualifying ledger event changed, so the daily score is unchanged. Coverage is selected and incomplete. |
| 2026-10-17 | 33.53 | +0.000 | Reviewed 17 October 2026: EIA still displays Brent spot $126.35 and WTI $104.71 for the 15 October close, two calendar days old and below the stale threshold. Only Brent is scored. OPEC annual crude reserves (1,572.46 billion barrels), production (74.85 million barrels/day) and the IEA 25% projected 2035 copper gap were reverified unchanged. IRENA retrieval failed; its 5,149 GW end-2025 observation and successful 15 October review date are retained. IMO remains at 113 confirmed incidents and 24 fatalities as of 14 October, with evacuation paused. UN Palestine warns of risks to the existing Gaza ceasefire; indexed DPPA describes continuing Sudan escalation, but direct DPPA retrieval failed. No qualifying new interstate-conflict onset/end or seven-day route change was verified. FDA's novel-drug index remains latest through Hovilpri on 9 October; biologics entries are guidance. The Brytly approval detail now loads and confirms first nonprescription apraclonidine, not by itself a first therapeutic mechanism. EMA's six CHMP recommendations remain recommendations; no qualifying reversal was verified in the selected safety checks. The broader research scan covered NASA's ISS experiment activation, indexed robotic sensor-skin and optoacoustic papers, Google's laboratory-agent prototypes and Tesla's indexed official Rocket claims. Direct Nature articles failed; Tesla's direct pages exposed only footnotes or no content. Nature's gene-therapy index differed from its search snapshot. Announcements, experimental components, experiment starts and manufacturer claims receive no milestone credit. Hovilpri's novelty hold remains; the existing valve event stays active once. No comparable scoring input changed, so the daily score is unchanged. Coverage is selected and incomplete. |
| 2026-10-16 | 33.53 | +0.010 | Reviewed 16 October 2026: EIA verifies Brent spot $126.35 and WTI $104.71 for the 15 October close. Only Brent is scored; its decline from $126.55 slightly reduces the oil-pressure penalty. The alternate-case EIA URL timed out, but the configured lowercase URL succeeded. OPEC annual crude reserves (1,572.46 billion barrels), production (74.85 million barrels/day) and the IEA 25% projected 2035 copper gap were reverified unchanged. IRENA retrieval failed; its end-2025 capacity of 5,149 GW and successful 15 October review date are retained. IMO remains at 113 confirmed incidents and 24 fatalities as of 14 October, with evacuation still paused. Indexed UN updates describe a fragile year-old Gaza ceasefire and continuing Yemen fighting, not a new qualifying interstate-conflict onset/end or verified seven-day route change; direct UN, UNSCO and DPPA retrievals failed. FDA's novel-drug list remains latest through Hovilpri on 9 October. Its Anktiva decision expands an existing bladder-cancer indication. Indexed FDA material reports Brytly approval on 16 October, but the detail page failed and first-mechanism eligibility is not established, so no credit is added. EMA's six CHMP recommendations are not final authorisations; Rasonque already had an August FDA approval. The Ibrance application withdrawal does not remove its authorised uses; its page has conflicting withdrawal dates. Selected NEJM searches found the October issue's gene-editing trial was first published in June; direct trial and AAV safety-letter pages failed, and PubMed returned no abstract. No new independently replicated capability milestone or qualifying reversal was verified. Hovilpri remains held for unresolved novelty. The existing valve event remains active once. Coverage is selected and incomplete. |
| 2026-10-15 | 33.52 | -0.060 | Reviewed 15 October 2026: EIA verifies Brent spot $126.55 and WTI $101.91 for the 14 October close. Only Brent is scored; its rise from $125.78 increases the fixed oil-pressure penalty. The lowercase EIA URL timed out twice, but the same primary page at /TodayinEnergy/prices.php loaded successfully. OPEC annual crude reserves (1,572.46 billion barrels), production (74.85 million barrels/day) and the IEA 25% projected 2035 copper gap were reverified unchanged. IRENA direct retrieval succeeded and reconfirmed 5,149 GW at end-2025; its review date is now 15 October, not its observation date. IMO reports 113 confirmed incidents and 24 fatalities as of 14 October. Its latest listed incidents on 13 October include GFS PRIDE sinking and damage to GFS GISELLE and AL SAADIYAT. The regional page still reports disruption and a paused evacuation plan; no newly qualifying interstate-conflict onset/end or verified seven-day route change was established. Indexed UN material through 14 October was screened, but direct retrieval of the noon briefing failed. FDA's novel-drug list remains latest through Hovilpri on 9 October; biologics additions through 14 October are guidance. FDA device-safety listings exposed no reversal of the credited valve event. EMA's 15 October Opuviz update concerns an aflibercept biosimilar authorised in November 2024, not a new mechanism. Selected Nature searches surfaced early trials and older research, not an independently replicated capability milestone; the drug-development index redirected to an inaccessible identity page. Hovilpri's indication-specific mechanism novelty remains unresolved and uncredited. The existing valve event remains active once. Coverage is selected and incomplete. |
| 2026-10-14 | 33.58 | +0.380 | Reviewed 14 October 2026: EIA reports Brent spot $125.78 and WTI $100.86 for the 13 October close. Only Brent is scored; its verified decline from $130.18 reduces the fixed oil-pressure penalty. OPEC annual crude reserves (1,572.46 billion barrels), production (74.85 million barrels/day) and the IEA 25% projected 2035 copper gap were reverified unchanged. IRENA retrieval failed again; its dated 5,149 GW end-2025 capacity record and 23 September review date are retained. IMO remains at 106 confirmed incidents and 24 fatalities as of 13 October; the latest listed damage reports are ANGOLA PROSPERITY and PETRO DOLPHIN on 11 October, with two seafarers missing from PETRO DOLPHIN. IMO still reports continuing instability, affected seafarers and a paused evacuation plan, but no qualifying new interstate-conflict onset/end or newly verified seven-day route closure/reopening was established. The 14 October UN daily briefing could not be retrieved; accessible UN primary listings through 12 October showed ongoing conflict conditions but no qualifying new onset, end or route-status event. FDA's novel-drug list remains latest through the 9 October Hovilpri approval; its 14 October biologics entries are blood-donor compliance guidance, not approvals or reversals. EMA's 14 October entries are medicine-page updates, workshops, paediatric investigation plans and guidance rather than a new qualifying first approval or withdrawal. Selected primary-literature searches found older phase 1 and review records but no new first approval or independently replicated capability milestone. The existing valve event remains active once. Coverage is selected and incomplete. |
| 2026-10-13 | 33.20 | +0.000 | Reviewed 13 October 2026: EIA still displays Brent spot $130.18 and WTI $98.26 for the 8 October close; the quote is five calendar days old, below the seven-day stale threshold, and the page normally excludes federal holidays. OPEC annual crude reserves (1,572.46 billion barrels), production (74.85 million barrels/day) and the IEA 25% projected 2035 copper gap were reverified unchanged. IRENA retrieval failed again; its dated 5,149 GW end-2025 capacity record and 23 September review date are retained. IMO increased its confirmed incident list to 106 with 24 fatalities as of 13 October; the latest listed damage reports are ANGOLA PROSPERITY and PETRO DOLPHIN on 11 October, with two seafarers missing from PETRO DOLPHIN. IMO also reports continuing instability, affected seafarers and a paused evacuation plan, but no qualifying new interstate-conflict onset/end or newly verified seven-day route closure/reopening was established. Selected UN listings showed ongoing conflict conditions but no qualifying new onset, end or route-status event. FDA's novel-drug list remains latest through the 9 October Hovilpri approval, and its biologics list is also latest through 9 October. EMA's 12-13 October entries are updates, meeting material, medicine-page changes and a concept paper rather than a new qualifying approval or reversal. A 13 October Nature pain-management review was not new original evidence or an independently replicated capability milestone. The existing valve event remains active once. No verified daily-v1 scoring input changed, so the score is unchanged. Coverage is selected and incomplete. |
| 2026-10-12 | 33.20 | +0.000 | Reviewed 12 October 2026: EIA still displays Brent spot $130.18 and WTI $98.26 for the 8 October close; the quote is four calendar days old, below the seven-day stale threshold, and the page normally excludes federal holidays. OPEC annual crude reserves (1,572.46 billion barrels), production (74.85 million barrels/day) and the IEA 25% projected 2035 copper gap were reverified unchanged. IRENA retrieval failed again; its dated 5,149 GW end-2025 capacity record and 23 September review date are retained. IMO increased its confirmed incident list to 104 with 24 fatalities as of 12 October; the latest listed damage is VALTHERA on 10 October. IMO also reports continuing instability, affected seafarers and a paused evacuation plan, but no qualifying new interstate-conflict onset/end or newly verified seven-day route closure/reopening was established. FDA's novel-drug list remains latest through the 9 October Hovilpri approval; biologics and EMA indexes exposed no newer qualifying approval or reversal. Targeted primary-literature searches found no independently replicated capability milestone. The existing valve event remains active once. Monday's slower audit rechecked all 12 human-dimension sources, nature and planetary-boundary records, ESA satellite statistics, 12 major-economy 10-year yields, IMF/OECD debt context and selected medical records. ESA and yield observations were updated as context only; no verified daily-v1 scoring input changed, so the score is unchanged. Coverage is selected and incomplete. |
| 2026-10-11 | 33.20 | +0.000 | Reviewed 11 October 2026: EIA still displays Brent spot $130.18 and WTI $98.26 for the 8 October close; the quote is three calendar days old, below the seven-day stale threshold. OPEC annual crude reserves (1,572.46 billion barrels), production (74.85 million barrels/day) and the IEA 25% projected 2035 copper gap were reverified unchanged. IRENA retrieval failed again; its dated 5,149 GW end-2025 capacity record and 23 September review date are retained. IMO remains at 100 confirmed incidents and 24 fatalities as of 9 October. The UN Security Council's 9 October Middle East meeting and an indexed DPPA weekly brief were screened. DPPA describes Yemen as returned to full-scale war, but this is escalation of an existing internal conflict, not a verified new interstate-conflict onset/end under daily-v1; the direct DPPA page returned 403. No qualifying seven-day route closure or reopening was verified. FDA's drug, biologics and press indexes remain latest through 9 October and expose no new qualifying approval or reversal after Hovilpri; its score credit remains held for unresolved indication-specific mechanism novelty. EMA's current index remains latest through 9 October. A 9 October Nature Communications first-in-human roginolisib study reports 44 treated participants across dose-escalation and uveal-melanoma cohorts; it is an early trial, not an independently replicated capability milestone. The existing valve event remains active once. No verified scoring input changed, so daily-v1 is unchanged; coverage is selected and incomplete. |
| 2026-10-10 | 33.20 | +0.000 | Reviewed 10 October 2026: EIA still displays Brent spot $130.18 and WTI $98.26 for the 8 October close; the quote is two days old, below the seven-day stale threshold. OPEC annual crude reserves (1,572.46 billion barrels), production (74.85 million barrels/day) and the IEA 25% projected 2035 copper gap were reverified unchanged. IRENA retrieval failed again; its dated capacity record and prior review date are retained. IMO remains at 100 confirmed incidents and 24 fatalities as of 9 October. UN listings and an indexed DPPA weekly brief were screened, but full DPPA retrieval failed; no qualifying new interstate-conflict onset/end or seven-day route change was verified. FDA confirms the 9 October Hovilpri (pritelivir) approval. Credit is held pending indication-specific novelty verification: NCI identifies its helicase-primase mechanism, while Maruho documents an earlier Japanese approval of that class for recurrent HSV; indexed PMDA records corroborate the date but both PDF retrievals failed. This is not a claim that the drugs or approved populations are identical. FDA's atezolizumab regimen update and immune-globulin lot withdrawal, plus EMA's Ocrevus safety notice and other update listings, did not establish a qualifying new mechanism or reversal of a credited achievement. EMA's detailed safety PDF and FDA's device-safety index were unavailable. Selected primary research searches found no independently replicated capability milestone. The existing valve event remains active once. No verified scoring input changed, so daily-v1 is unchanged; coverage is selected and incomplete. |
| 2026-10-09 | 33.20 | -0.360 | Reviewed 9 October 2026: EIA reports Brent spot at $130.18 and WTI at $98.26 for the 8 October close. Only Brent is scored; its verified increase raises the fixed oil-pressure penalty. OPEC annual crude reserves (1,572.46 billion barrels), production (74.85 million barrels/day) and the IEA 25% projected 2035 copper gap were reverified unchanged. IRENA's direct primary release again returned an internal retrieval error, so the 5,149 GW observation and its 23 September review date remain. IMO reports 100 confirmed incidents and 24 fatalities as of 9 October, with the latest listed incident dated 6 October; no independently monitored new interstate-conflict onset/end or seven-day route closure/reopening was verified. The UN Security Council programme shows Middle East and Yemen meetings on 9 October, while the current primary report list exposed no qualifying route-status or conflict event. FDA's press index still ends with the 5 October ibogaine research request. Its biologics page posted a 7 October NUWIQ supplemental approval on 9 October, but the letter changes dosage and administration labeling for an existing product, not a first approval of a new mechanism. FDA's current BLA and cellular/gene-therapy lists showed no newer qualifying first approval or reversal. EMA's 9 October entries were paediatric investigation-plan and procedural updates, not initial authorisations or withdrawals. Selected primary research and regulator searches found no first approval or independently replicated capability milestone. Selected coverage is incomplete; the existing FDA valve event remains active once, with no duplicate, trial-only, announcement-only or headline-sentiment credit. |
| 2026-10-08 | 33.56 | -0.050 | Reviewed 8 October 2026: EIA reports Brent spot at $126.00 and WTI at $95.02 for the 7 October close. Only Brent is scored; its verified increase slightly raises the fixed oil-pressure penalty. OPEC annual crude reserves (1,572.46 billion barrels), production (74.85 million barrels/day) and the IEA 25% projected 2035 copper gap were reverified unchanged. IRENA's indexed primary release still exposes the 5,149 GW observation, but direct retrieval returned an internal error, so its 23 September review date remains. IMO still reports 93 confirmed incidents and 24 fatalities as of 6 October; no independently monitored interstate-conflict onset/end or seven-day route closure/reopening was verified. Targeted UN Security Council schedules and primary report listings exposed no qualifying new event. FDA's press index still ends with the 5 October ibogaine request; its biologics and device indexes showed no new qualifying approval or reversal. FDA's 7 October tucatinib approval is a maintenance combination using an already approved drug and HER2-targeted mechanism, not a first mechanism approval under daily-v1. EMA's current index exposed medicine-page and safety-review updates through 7 October but no new initial authorisation or market withdrawal. Japan's primary registry lists a 12-participant phase I/II Parkinson's gene-therapy study as suspended on 7 October, without results or a stated reason on the reviewed record; it was never scored and does not support a cure or reversal. Selected primary paper and trial searches found no first approval or independently replicated capability milestone. Selected coverage is incomplete; the existing FDA valve event remains active once, with no duplicate, trial-only or headline-sentiment credit. |
| 2026-10-07 | 33.61 | +0.000 | Reviewed 7 October 2026: EIA reports Brent spot at $125.44 and WTI at $96.24 for the 6 October close. Only Brent is scored; its small verified decline changes the fixed oil-pressure term without changing the rounded daily score. OPEC annual crude reserves (1,572.46 billion barrels), production (74.85 million barrels/day) and the IEA 25% projected 2035 copper gap were reverified unchanged. IRENA's direct release returned an internal retrieval error, so the 5,149 GW observation and its 23 September review date remain. IMO reports 93 confirmed incidents and 24 fatalities as of 6 October; the latest listed incidents occurred on 4 October, but no independently monitored interstate-conflict onset/end or seven-day route closure/reopening was verified. Targeted UN Security Council schedules and dated reports exposed no qualifying new event. FDA's current press index still ends with the 5 October ibogaine request for information; its biologics, novel-drug, device-update, safety-communication and drug-alert indexes showed no new qualifying approval or reversal. EMA's 7 October index contained updates to existing medicine pages and safety-review records; the accessible Cenrifki record confirms its authorisation was issued on 19 June 2026, not a new daily event. Two selected EMA detail pages and one follow-up retrieval failed. Selected primary research searches found an open-label 10-participant Parkinson's phase 1 study, but no first approval or independently replicated capability milestone. Selected coverage is incomplete; the existing FDA valve event remains active once, with no duplicate, trial-only or headline-sentiment credit. |
| 2026-10-06 | 33.61 | +0.870 | Reviewed 6 October 2026: EIA reports Brent spot at $125.51 and WTI at $96.13 for the 5 October close. Only Brent is scored; its verified decline from the prior $135.51 observation reduces the fixed oil-pressure penalty. OPEC annual crude reserves (1,572.46 billion barrels), production (74.85 million barrels/day) and the IEA 25% projected 2035 copper gap were reverified unchanged. IRENA's direct release returned an internal retrieval error, so the 5,149 GW observation and its 23 September review date remain. IMO's list now reports 93 confirmed incidents and 24 fatalities as of 5 October, but no independently monitored interstate-conflict onset/end or seven-day route closure/reopening was verified. Targeted UN Security Council results exposed current schedules and dated reports but no qualifying new event. FDA's current press index ends with the 5 October ibogaine request for information, while its biologics approval list and device-update index showed no new qualifying approval or reversal on 6 October. EMA's 6 October update index contained meetings, guidance and updates to existing medicine pages; Etcamah was authorised on 20 July and Orladeyo in 2021, so neither is a new daily event. One EMA detail page failed and follow-up requests were rate-limited. Selected primary research searches found no first approval or independently replicated capability milestone. Selected coverage is incomplete; the existing FDA valve event remains active once, with no duplicate, trial-only or headline-sentiment credit. |
| 2026-10-05 | 32.74 | -1.790 | Reviewed 5 October 2026: EIA reports Brent spot at $135.51 and WTI at $97.89 for the 2 October close. Only Brent is scored; its verified 18.0% one-session jump materially increases the fixed oil-pressure penalty. OPEC annual crude reserves (1,572.46 billion barrels), production (74.85 million barrels/day) and the IEA 25% projected 2035 copper gap were reverified unchanged. IRENA's direct release returned 403, so the 5,149 GW observation and its 23 September review date remain. IMO reports 91 confirmed incidents and 24 fatalities as of 5 October, but no independently monitored interstate-conflict onset/end or seven-day route closure/reopening was verified. FDA's new 5 October ibogaine request for information seeks input on early-phase research and is not an approval; its safety index showed no newer qualifying withdrawal. EMA's main update index and accessible records showed existing-product, assessment and meeting material rather than a qualifying approval or withdrawal; two detail pages returned 429. Targeted UN, WHO, trial-registry and primary-literature searches found a six-participant Parkinson's phase 1/2 report, but it is uncontrolled, was terminated early and does not meet the first-approval or replicated-milestone rule. Monday's slower-source audit also reviewed all 12 human-dimension records, nature and planetary-boundary records, the ESA indexed portal date, 12 major-economy 10-year yields, IMF/OECD debt context and selected medical records. Selected coverage is incomplete; the existing FDA event remains active once, with no duplicate or headline-sentiment credit. |
| 2026-10-04 | 34.53 | +0.000 | Reviewed 4 October 2026: EIA still reports Brent spot at $114.82 and WTI at $99.77 for the 1 October close; weekend publication lag leaves the fixed oil-price contribution unchanged and the quote is three days old, below the seven-day stale threshold. OPEC annual crude reserves (1,572.46 billion barrels), production (74.85 million barrels/day) and the IEA 25% projected 2035 copper gap were reverified unchanged. IRENA's direct release was unavailable through the review fetch, so the 5,149 GW observation and its 23 September review date remain. IMO remains at 88 confirmed incidents and 24 fatalities as of 30 September; no qualifying interstate-conflict onset/end or seven-day route closure/reopening was verified. FDA's October press index still ends with the already-credited 1 October Autus valve, its drug-alert index contains no newer withdrawal, and EMA's latest entries remain dated 2 October and concern safety assessment, existing-product pages and paediatric plans. Targeted UN, WHO, trial-registry and primary-literature searches produced no verified new event or reversal. Selected coverage is incomplete; the existing FDA event remains active once, with no duplicate or forced score movement. |
| 2026-10-03 | 34.53 | +0.000 | Reviewed 3 October 2026: EIA still reports Brent spot at $114.82 and WTI at $99.77 for the 1 October close; weekend publication lag leaves the fixed oil-price contribution unchanged and the quote is two days old, below the seven-day stale threshold. OPEC annual crude reserves (1,572.46 billion barrels), production (74.85 million barrels/day) and the IEA 25% projected 2035 copper gap were reverified unchanged. Indexed IRENA material still corroborates 5,149 GW, but direct retrieval returned 403, so its 23 September review date remains. IMO remains at 88 confirmed incidents and 24 fatalities as of 30 September; no qualifying interstate-conflict onset/end or seven-day route closure/reopening was verified. FDA's latest press announcement remains the already-credited 1 October Autus valve; the novel-drug list ends 28 September, and 2 October biologics items are administrative procedures and reporting codes. EMA's 2 October entries are safety assessment, product-page and paediatric-plan updates, not qualifying approvals or withdrawals. Targeted UN, safety, trial-registry and primary-literature searches produced no verified new event or reversal. Selected coverage is incomplete; the existing FDA event remains active once, with no duplicate or forced score movement. |
| 2026-10-02 | 34.53 | +0.720 | Reviewed 2 October 2026: EIA Brent spot fell from $115.91 to $114.82 per barrel at the 1 October close; WTI rose from $97.18 to $99.77 (context only). The FDA approved the Autus Size-Adjustable Valve on 1 October for pediatric congenital pulmonary valve disease; its first post-surgical expansion mechanism qualifies for one jurisdiction-specific first-approval event (+0.625), with 62 enrolled patients, six-month primary follow-up and only two reported expansions explicitly retained as limits. OPEC annual crude reserves (1,572.46 billion barrels), production (74.85 million barrels/day) and the IEA 25% projected 2035 copper gap were reverified unchanged. Indexed IRENA material still corroborates 5,149 GW but direct retrieval returned 403, so its earlier review date is retained. IMO remains at 88 confirmed incidents and 24 fatalities as of 30 September; no qualifying conflict or seven-day route change was established. EMA's 28 September–1 October PRAC summary reports no referral started or concluded. UN News retrieval was blocked. Selected coverage is incomplete; no duplicate, headline-sentiment or trial-only credits were added. |
| 2026-10-01 | 33.81 | -0.170 | Reviewed 1 October 2026: EIA Brent spot rose from $113.96 to $115.91 per barrel at the 30 September close; WTI rose from $96.16 to $97.18 (context only). Only the fixed Brent term changes. OPEC annual crude reserves (1,572.46 billion barrels) and production (74.85 million barrels/day) and the IEA 25% projected 2035 copper gap were reverified unchanged. Indexed IRENA material corroborated 5,149 GW but direct retrieval failed; its earlier full-page review date is retained. IMO lists 88 incidents as of 30 September; no qualifying conflict or seven-day route change was established. FDA pediatric Camzyos is an existing mechanism/condition expansion; BIVIGAM/ASCENIV supplements change specifications. EMA updates and an indexed primary mouse gene-delivery abstract produced no qualifying research event. UN detailed retrieval and direct Nature article access failed. Selected coverage is incomplete; no event credits or reversals were added. |
| 2026-09-30 | 33.98 | +0.520 | Reviewed 30 September 2026: EIA Brent spot fell from $119.97 to $113.96 per barrel at the 29 September close; WTI spot fell from $99.37 to $96.16 (context only). Only the fixed Brent price term changes. OPEC annual reserves and crude production were reverified unchanged. IMO now lists 86 incidents as of 29 September, including a pre-baseline 28 September incident; no qualifying route or conflict event was verified. FDA, EMA and two primary Parkinson’s/Crohn’s papers were screened without a qualifying scored achievement or withdrawal. IRENA retrieval failed; the IEA executive summary did not expose the retained 25% copper figure and its PDF failed. UN index opened but linked detailed coverage failed. Retained values keep their earlier review dates. Selected coverage is incomplete; no headline sentiment or duplicate event points were added. |
| 2026-09-29 | 33.46 | Baseline | Reviewed 29 September 2026: EIA Brent spot rose from $116.01 to $119.97 per barrel at the 28 September close; this alone lowers the daily score by 0.341 points. WTI spot updated to $99.37 as context. OPEC annual reserves and production and the IEA copper scenario were rechecked unchanged. FDA, EMA and IMO sources were scanned; no qualifying post-baseline event was verified. IRENA retrieval failed (403); its dated value is retained. UN retrieval and wider research search coverage were incomplete. This is a same-day update to the initial baseline calculation, not a previous-day comparison. |
Only actual calculations are recorded. There is no backfilled daily history. Same-day corrections replace that day’s public row and are documented in the review log.
Formula, thresholds & limitations
Model daily-v1 is an editorial experiment, not a validated civilization measurement. Baseline 33.8 comes from Civilization Index v25; original model snapshot 22 September 2026. Comparison inputs were frozen on 2026-09-29 UTC. The baseline does not claim conditions that day were good or neutral.
Daily score = baseline + geopolitics + resources + research + oil-price contribution, bounded to 0–100. Each contribution is bounded to −2.5 to +2.5 points. Equal caps are editorial choices, not empirically estimated effects. The model does not establish causality, forecast crises, or represent all countries equally.
- Oil: −2.5 × clamp((Brent / baseline Brent − 1) / 0.25). A 25% spot-price rise reaches the negative cap; a 25% decline reaches the positive cap. This reflects importer affordability only. Falling prices can also signal recession or hurt producers; it is not an environmental score.
- Resources: 2.5 × the mean of three clamped changes: renewable capacity growth / 20%; proven crude reserve growth / 10%; and the reduction in projected copper deficit / 10 percentage points. Reference values: 5149 GW, 1572.46 billion barrels and 25%. Higher reserves mean a larger reported supply buffer in this narrow model, not permission to burn them or evidence of sustainability. Scenario revisions can move this component without new physical capacity.
- Geopolitics: 2.5 × clamp(sum of qualifying event units). A verified new interstate conflict or sustained closure of a major energy/trade route contributes −0.25 units; a verified conflict ending or sustained reopening contributes +0.25. Implementation must be confirmed for at least seven days; promises, individual attacks and duplicate reports receive no points. A reversal of a post-baseline event cancels its effect rather than earning a second bonus.
- Research: 2.5 × clamp(sum of qualifying event units). A first regulatory approval of a new therapeutic mechanism for a specified indication contributes +0.25; an independently replicated capability milestone +0.125. Withdrawal or retraction reverses that credit. Before-baseline withdrawals can contribute −0.25 or −0.125. Preprints, announcements, trial starts and unreplicated results receive zero. These are selected events, not a count of all science.
Here clamp limits a value to −1…+1. Events do not accumulate again each day or automatically expire. Corrections and reversals are logged. Sources and populations must remain comparable. Missing sources retain their last observation and its date; a repeated date is not new evidence.
Original milestone scores, the Progress Scale, human dimensions and learning proposals are separate. Research already reflected in a structural-score revision must not also receive a daily bonus; a future baseline reset requires a versioned explanation. This daily view is educational, not medical or investment advice.
Original model ↗ · Nature & resources ↗ · Medical research ↗ · Review status ↗